• 1
    Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992; 21: 113.
  • 2
    Bosch J, Garcia-Pagan JC. The splanchnic circulation in cirrhosis. In: GinesP, ArroyoV, RodesJ, SchrierRW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis, and Treatment. Malden, MA: Blackwell Publishing; 2005: 125136.
  • 3
    Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886894.
  • 4
    Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005; 43: 98103.
  • 5
    Angermayr B, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J, Fernandez M. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol 2006; 44: 10331039.
  • 6
    Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperemia in portal hypertensive rats. Gut 2007; 56: 560564.
  • 7
    Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353: 22542261.
  • 8
    Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 11531155.
  • 9
    Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389395.
  • 10
    Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685693.
  • 11
    Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669676.
  • 12
    Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 12831316.
  • 13
    Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128135.
  • 14
    Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995; 17: 666671.
  • 15
    Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935942.
  • 16
    Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 28112821.
  • 17
    Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493502.
  • 18
    Pietras K, Sjöblom T, Rubin K, Heldin CH, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439443.
  • 19
    Fernandez M, Garcia-Pagan JC, Casadevall M, Bernadich C, Piera C, Whittle BJ, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats. Gastroenterology 1995; 108: 14871495.
  • 20
    Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, Rodes J. Acute and chronic cyclooxygenase blockade in portal hypertensive rats: Influence on nitric oxide biosynthesis. Gastroenterology 1996; 110: 15291535.
  • 21
    Jimenez O, Campistol JM, Vidal E, Faura A, Oppenheimer F, Corbella J, Brunet M. Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation. Transplant Proc 2003; 35: 16861688.
  • 22
    Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 12871295.
  • 23
    Navasa M, Forns X, Sanchez V, Andreu H, Marcos V, Borras JM, Rimola A, et al. Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrosis after liver transplantation. J Hepatol 1996; 25: 129134.
  • 24
    Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 13881393.
  • 25
    Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003; 162: 183193.
  • 26
    Escorsell A, Bosch J. Pathophysiology of variceal bleeding. In: GroszmannRJ, BoschJ, eds. Portal Hypertension in the 21st Century. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2004: 155166.
  • 27
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. HEPATOLOGY 2003; 37: 902908.
  • 28
    D'Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006; 131: 16111624.